Inceptionr LLC Buys 57,485 Shares of Amicus Therapeutics, Inc. $FOLD

Inceptionr LLC increased its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 539.8% in the third quarter, HoldingsChannel reports. The fund owned 68,134 shares of the biopharmaceutical company’s stock after purchasing an additional 57,485 shares during the period. Inceptionr LLC’s holdings in Amicus Therapeutics were worth $537,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Osaic Holdings Inc. grew its position in Amicus Therapeutics by 450.1% during the 2nd quarter. Osaic Holdings Inc. now owns 4,104 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 3,358 shares during the last quarter. EverSource Wealth Advisors LLC grew its holdings in shares of Amicus Therapeutics by 472.6% in the second quarter. EverSource Wealth Advisors LLC now owns 4,455 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 3,677 shares during the last quarter. Strs Ohio purchased a new position in shares of Amicus Therapeutics in the first quarter worth $30,000. ANTIPODES PARTNERS Ltd purchased a new position in shares of Amicus Therapeutics in the third quarter worth $31,000. Finally, Versant Capital Management Inc raised its holdings in Amicus Therapeutics by 499.1% during the 3rd quarter. Versant Capital Management Inc now owns 5,266 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 4,387 shares during the last quarter.

Amicus Therapeutics Stock Performance

Shares of FOLD opened at $14.36 on Wednesday. Amicus Therapeutics, Inc. has a 52 week low of $5.51 and a 52 week high of $14.38. The company has a quick ratio of 1.88, a current ratio of 2.84 and a debt-to-equity ratio of 1.43. The stock has a market cap of $4.51 billion, a P/E ratio of -179.50 and a beta of 0.43. The business’s 50 day moving average price is $14.31 and its 200-day moving average price is $11.05.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings data on Friday, February 20th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.03). Amicus Therapeutics had a negative net margin of 4.27% and a positive return on equity of 4.15%. The firm had revenue of $185.21 million for the quarter, compared to the consensus estimate of $185.00 million. During the same quarter in the prior year, the business posted $0.09 earnings per share. The firm’s revenue for the quarter was up 23.7% compared to the same quarter last year. Equities research analysts anticipate that Amicus Therapeutics, Inc. will post 0.15 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

FOLD has been the subject of several analyst reports. Citigroup reissued a “neutral” rating and set a $14.50 price target (down from $17.00) on shares of Amicus Therapeutics in a research report on Monday, December 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Amicus Therapeutics in a research note on Monday, December 29th. Leerink Partners downgraded Amicus Therapeutics from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $17.00 to $14.50 in a report on Monday, December 29th. Jefferies Financial Group reaffirmed a “hold” rating and set a $14.50 price target (down from $16.00) on shares of Amicus Therapeutics in a research report on Thursday, January 22nd. Finally, Zacks Research cut Amicus Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, January 26th. Three investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Amicus Therapeutics has a consensus rating of “Hold” and an average target price of $15.39.

Insider Activity

In related news, insider David Michael Clark sold 25,643 shares of the stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $11.00, for a total transaction of $282,073.00. Following the transaction, the insider owned 271,332 shares in the company, valued at $2,984,652. This represents a 8.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Bradley L. Campbell sold 77,926 shares of the firm’s stock in a transaction on Monday, December 15th. The stock was sold at an average price of $10.86, for a total value of $846,276.36. Following the completion of the transaction, the chief executive officer owned 1,129,782 shares in the company, valued at approximately $12,269,432.52. This trade represents a 6.45% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 226,711 shares of company stock worth $2,887,822 in the last 90 days. Company insiders own 2.20% of the company’s stock.

About Amicus Therapeutics

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.